Clofarabine in Pediatric Acute Relapsed or Refractory Leukemia: Where Do We Stand on the Bridge to Hematopoietic Stem Cell Transplantation?

J Hematol · 2023 · PMC9990710 · PMID 36895294

Europe PMC DOI

hedged sentence

0.4280

closest p · 8.6× alpha

0.4280

boldest claim

The sentences

did not reach statistical significanceP = 0.428not close (p > 0.1)

Median time in months to receive the first cycle of CLOF was lower in AML as compared to ALL patients; however, it did not reach statistical significance (11.2 vs. 15.8, P = 0.428).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.